Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Oct 29;114(18):3956-9.
doi: 10.1182/blood-2009-07-231092. Epub 2009 Aug 27.

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

John Koreth  1 , Kristen E Stevenson, Haesook T Kim, Michael Garcia, Vincent T Ho, Philippe Armand, Corey Cutler, Jerome Ritz, Joseph H Antin, Robert J Soiffer, Edwin P Alyea 3rd
Affiliations
Clinical Trial

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

John Koreth et al. Blood. .

Abstract

Graft-versus-host disease (GVHD) is a significant complication of allogeneic stem cell transplantation (alloSCT). The proteasome inhibitor bortezomib has immunomodulatory properties of potential benefit for GVHD control. We undertook a phase 1 trial of bortezomib, tacrolimus, and methotrexate for GVHD prophylaxis after reduced-intensity conditioning alloSCT using human leukocyte antigen-mismatched unrelated donors. Twenty-three patients were enrolled. Bortezomib dose levels of 1, 1.3, and 1.5 mg/m2 were evaluated with 5, 3, and 5 patients, respectively. Ten additional patients were accrued at the 1.3 mg/m2 bortezomib dose level. Bortezomib-related toxicity was minimal. With a 12-month median follow-up, grade II-IV acute GVHD occurred in 3 patients, a 180-day cumulative incidence of 13%. Chronic GVHD occurred in 9 patients, a 1-year cumulative incidence of 41%. At 1-year, the nonrelapse mortality was zero, cumulative incidence of relapse/progression was 29%, and overall, progression-free, and event-free survival were 75%, 64%, and 59%, respectively. Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation. This study was registered at http://www.clinicaltrials.gov as #NCT00369226.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phase 1 trial outcomes. (A) Total donor chimerism at days +30, +100, and +180 after transplantation in patients without evidence of disease relapse/progression. Donor chimerism analysis was not mandated beyond day +100. The 2 patients with low initial donor chimerism of 54% and 0% had MPD. The protocol was subsequently amended to exclude MPD. (B) Cumulative incidence of grade II-IV acute GVHD and chronic GVHD with graft failure, relapse/progression, and death as competing events. (C) Overall and event-free survival (N = 23). Events include graft failure, relapse/progression, and death. (D) Cumulative incidence of graft failure and relapse/progression with death as a competing event.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12):3192–3204. - PubMed
    1. Ho V, Kim H, Windawi S, et al. HLA mismatch and clinical outcome after unrelated donor (URD) non-myeloablative hematopoeitic stem cell transplantation (NST). Biol Blood Marrow Transplant. 2005;11(suppl 1):S14.
    1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076. - PubMed
    1. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–260. - PubMed
    1. Wang X, Luo H, Chen H, Duguid W, Wu J. Role of proteasomes in T cell activation and proliferation. J Immunol. 1998;160(2):788–801. - PubMed

Publication types

MeSH terms

Associated data